このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

GKL-006Allo Injection in Patients With Advanced Solid Tumors

2026年7月14日 更新者:Beijing Gene Key Life Technology Co., Ltd

A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GKL-006Allo Injection in Patients With Solid Tumors

This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary anti-tumor activity of GKL-006Allo Injection in participants with advanced solid tumors.

調査の概要

状態

まだ募集していません

条件

介入・治療

詳細な説明

This Phase 1 study will evaluate GKL-006Allo Injection in participants with advanced or metastatic solid tumors who have failed or are intolerant to standard therapy.

The study includes single-dose and multiple-dose treatment, with a potential dose-expansion stage to further evaluate selected dose level according to protocol-specified criteria. The single-dose and multiple-dose stages are designed to characterize safety, tolerability, and biological activity across protocol-specified dose levels.

Participants will receive GKL-006Allo Injection according to the study protocol and will undergo scheduled safety monitoring, tumor assessments, pharmacokinetic and pharmacodynamic sampling, and immunogenicity testing during treatment and follow-up.

研究の種類

介入

入学 (推定)

27

段階

  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Cancer Hospital Chinese Academy of Medical Sciences
  • 電話番号:+86-316-5916013
  • メール:lining@cisams.ac.cn

研究場所

    • Beijing Municipality
      • Beijing、Beijing Municipality、中国、100021
        • Cancer Hospital Chinese Academy of Medical Sciences
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

説明

Inclusion Criteria:

  • Able to understand and voluntarily sign the informed consent form.
  • Aged 18 to 75 years.
  • Histologically, cytologically or clinical confirmed unresectable locally advanced or metastatic solid tumor that has failed standard therapy.
  • At least one measurable tumor lesion during screening according to RECIST v1.1.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 and life expectancy of at least 3 months.
  • Adequate hematologic and organ function.
  • Participants of childbearing potential must agree to use at least one medically accepted contraceptive method during study treatment and for 6 months after the end of study treatment.
  • Able to communicate with the investigator, comply with study visits, and understand and follow study requirements.

Exclusion Criteria:

  • Recently received radical radiotherapy or other anti-tumor therapy.
  • Known hypersensitivity to any component of the study treatment.
  • Prior history or concurrent malignancy that has not been cured.
  • Active infection, known or suspected autoimmune disease.
  • Last anti-tumor treatment toxicity not yet recovered to suitable status.
  • Other organ dysfunction or situations deemed inappropriate by the investigator.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:順次割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:GKL-006Allo Injection
Natural killer T cells (NKT) are a type of special lymphocyte discovered in recent years that mediate both innate and adaptive immunity, and are considered the fourth type of lymphocyte. GKL-006Allo is an allogeneic iNKT cell.
GKL-006Allo Injection is an allogeneic invariant natural killer T (iNKT) cell therapy. It will be administered according to the dose level, dosing schedule, and treatment stage specified in the protocol.
他の名前:
  • Allogeneic iNKT Cell Therapy
  • Allogeneic invariant natural killer T cell therapy

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Number of Participants With Dose-Limiting Toxicities (DLTs)
時間枠:From the first dose through the end of the DLT observation period, assessed up to 28 days.
Dose-limiting toxicities will be assessed according to protocol-defined DLT criteria.
From the first dose through the end of the DLT observation period, assessed up to 28 days.
Incidence and Severity of Adverse Events
時間枠:From the first dose of study treatment until 28 days after the pointed dose of study treatment. The safety monitor will be continued until the end of the study, up to 18 months.
Safety will be assessed by the incidence and severity of adverse events, serious adverse events, laboratory abnormalities, electrocardiogram abnormalities, physical examination findings, and vital sign abnormalities.
From the first dose of study treatment until 28 days after the pointed dose of study treatment. The safety monitor will be continued until the end of the study, up to 18 months.

二次結果の測定

結果測定
メジャーの説明
時間枠
Progression-Free Survival (PFS)
時間枠:From the first dose of study treatment until disease progression or death from any cause, whichever occurs first, assessed up to 18 months.
Progression-free survival is defined as the time from the first dose of study treatment to the first documented disease progression or death from any cause, whichever occurs first, according to RECIST v1.1.
From the first dose of study treatment until disease progression or death from any cause, whichever occurs first, assessed up to 18 months.
Overall Survival (OS)
時間枠:From the first dose of study treatment until death from any cause, assessed up to 18 months.
Overall survival is defined as the time from the first dose of study treatment to death from any cause.
From the first dose of study treatment until death from any cause, assessed up to 18 months.
Change From Baseline in EORTC QLQ-C30 Scale Scores
時間枠:Baseline and scheduled post-baseline assessments, up to 18 months.
Health-related quality of life will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). Scores for each scale range from 0 to 100. Higher scores on the functional scales and global health status/quality-of-life scale indicate better functioning or quality of life.
Baseline and scheduled post-baseline assessments, up to 18 months.
Immunogenicity
時間枠:From baseline through protocol-specified immunogenicity sampling time points, assessed up to 180 days.
GKL-006 Alloantibodies (ADA) and their titers, anti-GKL-006 Allo neutralizing antibodies (Nab) and their titers, anti-HLA antibodies, etc. will be tested.
From baseline through protocol-specified immunogenicity sampling time points, assessed up to 180 days.
Disease Control Rate (DCR)
時間枠:From the first dose of study treatment through scheduled tumor assessments, assessed up to 18 months.
Disease control rate is defined as the proportion of participants with a best overall response of complete response, partial response, or stable disease according to RECIST v1.1.
From the first dose of study treatment through scheduled tumor assessments, assessed up to 18 months.
Objective Response Rate (ORR)
時間枠:From the first dose of study treatment through scheduled tumor assessments, assessed up to 18 months.
Objective response rate is defined as the proportion of participants with a best overall response of complete response or partial response according to RECIST v1.1.
From the first dose of study treatment through scheduled tumor assessments, assessed up to 18 months.
Pharmacokinetic characterization of maximum observed plasma concentration (Cmax)
時間枠:From 60 minutes before the first dose through 150 days.
Maximum observed plasma concentration of GKL-006 following intravenous administration according to protocol.
From 60 minutes before the first dose through 150 days.
Pharmacokinetic characterization of time to maximum observed plasma concentration (Tmax)
時間枠:From 60 minutes before the first dose through 150 days.
Time to reach the maximum observed plasma concentration of GKL-006 following intravenous administration.
From 60 minutes before the first dose through 150 days.
Pharmacokinetic characterization of area under the plasma concentration-time curve (AUC)
時間枠:From 60 minutes before the first dose through 150 days.
Area under the plasma concentration-time curve of GKL-006 following intravenous administration.
From 60 minutes before the first dose through 150 days.
Pharmacokinetic characterization of terminal elimination half-life (t½)
時間枠:From 60 minutes before the first dose through 150 days.
Terminal elimination half-life of GKL-006 calculated from plasma concentration-time data following intravenous administration.
From 60 minutes before the first dose through 150 days.
Pharmacodynamic Biomarkers of NK cells
時間枠:From 60 minutes before the first dose through 150 days.
Immune cell subsets
From 60 minutes before the first dose through 150 days.
Pharmacodynamic Biomarkers of Peripheral blood TNF-α
時間枠:From 60 minutes before the first dose through 150 days.
Immune-related cytokines
From 60 minutes before the first dose through 150 days.
Pharmacodynamic Biomarkers of Peripheral blood IFN-γ
時間枠:From 60 minutes before the first dose through 150 days.
Immune-related cytokines
From 60 minutes before the first dose through 150 days.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Ning Li, MD、Cancer Institute and Hospital, Chinese Academy of Medical Sciences

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年8月30日

一次修了 (推定)

2028年9月30日

研究の完了 (推定)

2029年1月31日

試験登録日

最初に提出

2026年7月9日

QC基準を満たした最初の提出物

2026年7月14日

最初の投稿 (実際)

2026年7月15日

学習記録の更新

投稿された最後の更新 (実際)

2026年7月15日

QC基準を満たした最後の更新が送信されました

2026年7月14日

最終確認日

2026年6月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • GKL006ALLOST01

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。